Page 3 - Pigmentosa Pipeline Insight News Today : Breaking News, Live Updates & Top Stories | Vimarsana

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis
NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA).
The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively.
We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. ....

United States , Neena Haider , Sanjay Subramanian , Emmie Twombly , Mohamed Genead , Professor Of Ophthalmology At Harvard Medical School , European Commission , Schepens Eye Research Institute , Ocugen Inc , Exchange Commission , Head Of Corporate Development , Nuclear Hormone Receptors , European Union , Leber Congenital , Chief Executive Officer , Retina Scientific Advisory Board , Acting Chief Medical Officer , Hormone Receptors , Associate Professor , Harvard Medical School , Associate Scientist , Massachusetts Eye , Bharat Biotech , Private Securities Litigation Reform Act , Financial Officer , Corporate Development ,